1. Lai, A. C. & Crews, C. M. Induced Protein Degradation: an Emerging Drug Discovery Paradigm. Nat. Rev. Drug Discov. 16, 101-114 (2017).
2. Dale, B. et al. Advancing Targeted Protein Degradation for Cancer Therapy. Nat. Rev. Cancer 21, 638-654 (2021).
3. Chamberlain, P. P. & Hamann, L. G. Development of Targeted Protein Degradation Therapeutics. Nat. Chem. Biol. 15, 937-944 (2019).
4. Pettersson, M. & Crews, C. M. PROteolysis TArgeting Chimeras (PROTACs)-Past, Present and Future. Drug Discov. Today 31, 15-27 (2019).
5. Skaar, J. R., Pagan, J. K. & Pagano, M. SCF Ubiquitin Ligase-Targeted Therapies. Nat. Rev. Drug Discov. 13, 889-903 (2014).
6. Sakamoto, K. M. et al. Protacs: Chimeric Molecules that Target Proteins to the Skp1–Cullin–F Box Complex for Ubiquitination and Degradation. Proc. Natl Acad. Sci. USA 98, 8554 (2001).
7. Burslem, G. M. & Crews, C. M. Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery. Cell 181, 102-114 (2020).
8. Backus, K. M. et al. Proteome-Wide Covalent Ligand Discovery in Native Biological Systems. Nature 534, 570-574 (2016).
9. Popovic, D., Vucic, D. & Dikic, I. Ubiquitination in Disease Pathogenesis and Treatment. Nat. Med. 20, 1242-1253 (2014).
10. Schapira, M., Calabrese, M. F., Bullock, A. N. & Crews, C. M. Targeted protein degradation: expanding the toolbox. Nat. Rev. Drug Discov. 18, 949-963 (2019).
11. Neklesa, T. K., Winkler, J. D. & Crews, C. M. Targeted Protein Degradation by PROTACs. Pharmacol Ther 174, 138-144 (2017).
12. Bushweller, J. H. Targeting Transcription Factors in Cancer-from Undruggable to Reality. Nat. Rev. Cancer 19, 611-624 (2019).
13. Raina, K. et al. PROTAC-induced BET Protein Degradation as a Therapy for Castration-Resistant Prostate Cancer. Proc. Natl Acad. Sci. USA 113, 7124-7129 (2016).
14. Lu, J. et al. BRD4 Degradation By Protacs Represents a More Effective Therapeutic Strategy Than BRD4 Inhibitors in DLBCL. Blood 126, 2050-2050, (2015).
15. Moreau, K. et al. Proteolysis-Targeting Chimeras in Drug Development: A safety perspective. Br J Pharmacol 177, 1709-1718 (2020).
16. Reynders, M. et al. PHOTACs Enable Optical Control of Protein Degradation. Sci. Adv. 6, eaay5064 (2020).
17. Cotton, A. D., Nguyen, D. P., Gramespacher, J. A., Seiple, I. B. & Wells, J. A. Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1. J Am Chem Soc 143, 593-598 (2021).
18. Pillow, T. H. et al. Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity. ChemMedChem 15, 17-25 (2020).
19. Banik, S. M. Nature 584 (2020).
20. Maneiro, M. A. et al. Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4. ACS Chem. Biol. 15, 1306-1312 (2020).
21. Liu, J. et al. Cancer Selective Target Degradation by Folate-Caged PROTACs. J Am Chem Soc 143, 7380-7387 (2021).
22. He, S. et al. Aptamer-PROTAC Conjugates (APCs) for Tumor-Specific Targeting in Breast Cancer. Angew. Chem. Int. Ed., (2021).
23. Xue, G., Wang, K., Zhou, D., Zhong, H. & Pan, Z. Light-Induced Protein Degradation with Photocaged PROTACs. J Am Chem Soc 141, 18370-18374 (2019).
24. Liu, J. et al. Light-induced Control of Protein Destruction by Opto-PROTAC. Sci. Adv. 6, eaay5154 (2020).
25. Hou, B. et al. Engineering Stimuli-Activatable Boolean Logic Prodrug Nanoparticles for Combination Cancer Immunotherapy. Adv. Mater 32, e1907210 (2020).
26. Zhou, F. et al. Engineering Chameleon Prodrug Nanovesicles to Increase Antigen Presentation and Inhibit PD-L1 Expression for Circumventing Immune Resistance of Cancer. Adv. Mater 33, 2102668 (2021).
27. Wang, Y. et al. A Nanoparticle-Based Strategy for the Imaging of a Broad Range of Tumours by Nonlinear Amplification of Microenvironment Signals. Nat Mater 13, 204-212 (2014).
28. Yang, B., Gao, J., Pei, Q., Xu, H. & Yu, H. Engineering Prodrug Nanomedicine for CancerImmunotherapy. Adv Sci 7, 2002365 (2020).
29. Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery Technologies for Cancer Immunotherapy. Nat. Rev. Drug Discov. 18, 175-196 (2019).
30. Ma, X. et al. Ultra-pH-Sensitive Nanoprobe Library with Broad pH Tunability and Fluorescence Emissions. J Am Chem Soc 136, 11085-11092 (2014).
31. Wang, Y. et al. Disulfide Bond Bridge Insertion Turns Hydrophobic Anticancer Prodrugs into Self-assembled Nanomedicines. Nano Lett 14, 5577-5583 (2014).
32. Feng, B. et al. Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment. Adv. Mater 30, 1803001 (2018).
33. Wang, W. et al. In situ Activation of Therapeutics Through Bioorthogonal Catalysis. Adv Drug Deliv Rev 176, 113893 (2021).
34. Qin, H. et al. Development of a Cancer Vaccine Using In Vivo Click-Chemistry-Mediated Active Lymph Node Accumulation for Improved Immunotherapy. Adv. Mater 33, 2006007 (2021).
35. Wang, H. et al. Metabolic Labeling and Targeted Modulation of Dendritic Cells. Nat Mater 19, 1244-1252 (2020).
36. Bai, L. et al. Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. Cancer Res 77, 2476-2487 (2017).
37. Donati, B., Lorenzini, E. & Ciarrocchi, A. BRD4 and Cancer: Going Beyond Transcriptional Regulation. Molecular Cancer 17, 164 (2018).
38. Cochran, A. G., Conery, A. R. & Sims, R. J., 3rd. Bromodomains: a New Target Class for Drug development. Nat. Rev. Drug Discov. 18, 609-628 (2019).
39. Wang, D. et al. Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy. Nano Lett 16, 5503-5513 (2016).
40. Wang, T. et al. Intracellularly Acid-Switchable Multifunctional Micelles for Combinational Photo/Chemotherapy of the Drug-Resistant Tumor. ACS Nano 10, 3496-3508 (2016).
41. Liu, J., Chen, Q., Feng, L. & Liu, Z. Nanomedicine for Tumor Microenvironment Modulation and Cancer Treatment Enhancement. Nano Today 21, 55-73 (2018).
42. Zhou, F. et al. Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade. Adv. Mater 31, 1805888 (2019).
43. Piya, S. et al. BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects. Blood 128, 748-748 (2016).
44. Song, R. et al. Acidity-Activatable Dynamic Nanoparticles Boosting Ferroptotic Cell Death for Immunotherapy of Cancer. Adv. Mater 33, 2101155 (2021).
45. Feng, B. et al. Self-Amplified Drug Delivery with Light-Inducible Nanocargoes to Enhance Cancer Immunotherapy. Adv. Mater 31, 1902960 (2019).